Anthropometric measurements were obtained on 126 male nonathletic first year university students (N-1), 178 male nonathletic third year university students (N-3) and 114 male athletic third year university students (A) . The mean values of height and body weight for group A were significantly larger than those for groups N-1 and N-3. Group A showed significant larger mean values of girth of chest, abdomen, thigh and upper arm than groups N-1 and N-3. Physical status of group N-1 was a little shorter and slender than that of group N-3. Group A showed significantly greater mean values of Rohrer's index and Brugsch's index than groups N-1 and N-3. The mean values of skinfold thickness and body fat (%) caluculated by using prediction formula from mean skinfold thickness for group A were significantly smaller than those for group N-3 and were essentially the same as those for group N-1. Bigger physique and smaller body fat content of athletes could be explained as due to a result of physical training and might be considered as the cause of superior physical fitness of athletes.
The following prediction equations for standard body weight (W) from height (H) using mean values of body weight and height (W and H) and their standard deviations (cW and aH) are proposed for the evaluation of overweight and underweight.
W=3W/HH-2W
and W=σW/σHH-σW/σHH+W
Plotting of body weight and body fat content in standard measure against height in standard measure was used to compare physical characteristics of athletes with those of nonathletes.

Anthropometrical measurement were obtained on 178 male nonathletic university students and 168 male athletic university students (Swimming, Handball, Soccer, Rugby, Running, Thrower, Judo and Gymnastics) aged 18-22 years.
The results obtained were as follows
The mean values of height and body weight for nonathletes were 170.2cm and 59.7kg respectively. The mean values of height and body weight for athletes except gymnastics and long distance runner were larger than those for nonathletes. Athletes showed larger mean values of girth of chest than nonathletes (86.1cm) . The mean values of girth of upper arm and girth of thigh for nonathletes were 26.9cm and 50.6cm respectively. The mean values of girth of upper arm for athletes except basketball, long distance runner and jumper were considerably larger than that for nonathletes. Athletes except long distance runner, jumper and gymnastics showed larger mean values of thigh than nonathletes. The mean values of skinfold thickness for athletes except heavy weight class of judo were thinner than that for nonathletes and the percentage of body fat calculated by using the prediction formura from mean skinfold thickness, body surface area and body weight for athletes was smaller than that for nonathletes
Plotting of body weight and body fat content in standard measure against height in standard measure with family of iso-deviation line was used to compare the body composition and body shape of athletes with those of nonathletes. In this plotting, physical characteristics could be expressed as the difference (R) between the points representing the mean value of athletes on the origin, (the mean values of nonathletes) and ratio of deviation (r) from standard line representing correlation of body weight or body fat content to height for nonathletes. Plotting R against r with family of lines of the same height was proposed to differentiate physical characteristics of athletes participating in different kinds of sports and to evaluate the effect of training on physical characteristics. Plotting of girth of upper arm and girth of thigh in standard measure against girth of chest was used for the evaluation of difference in body shape of athletes.

This study was performed to evaluate the effect of betatricalcium phosphate and poly L-lactide-co-glycolide-coepsilon- caprolactone (TCP/PLGC) membrane in the repair of partial bone defects in canine proximal humerus. Three adult mixed-breed dogs were used during the experimental period. The length of the defect was quarter of the full length of humerus, and width of the defect was quarter of middle diameter of the lateral aspect of humerus. The humeri of each dog were divided into treatment (TCP/ PLGC) and control groups. The defect was covered with TCP/PLGC membrane in treatment group. To evaluate regeneration of the bone, computerized tomography (CT) and histopathologic examination were performed. The radiopaque lines were appeared at the original defect sites in TCP/PLGC group but below the original site in control at 4th week. Radiopacity and thickness of the defect sites, and radiopaque lines were more increased at 8th week than those of 4th week. Histopathologic findings revealed fibrous connective tissue migration into the defect and the migration inhibited the structure of new cortex to be placed in the original level in control whereas new cortex growth was found in the level of original line in TCP/ PLGC group. However, the new cortical bone in the TCP/ PLGC group was thinner and less organized than the adjacent intact cortex, and the amount of new cancellous bones were also scanty. The result suggested that TCP/ PLGC membrane is a good guided bone regeneration material to restore the original morphology of humerus in partial defect.
Absorbable Implants/veterinary ; Animals ; Bone Regeneration/*drug effects ; Calcium Phosphates/*pharmacology ; Dogs/*surgery ; Guided Tissue Regeneration/methods/*veterinary ; Histocytochemistry/veterinary ; Humerus/*surgery ; Male ; Polyesters/*pharmacology ; Tomography, X-Ray Computed/veterinary ; Wound Healing/physiology

Objective: The primary objective of this study was to evaluate the safety of niraparib 300 mg/day in Japanese patients with platinum-sensitive, relapsed ovarian cancer in a maintenance setting. Methods: Phase 2, multicenter, open-label, single-arm study enrolled Japanese patients with platinum-sensitive, relapsed ovarian cancer who had received ≥2 platinum-based regimens.The primary endpoint (incidence of grade 3 or 4 thrombocytopenia-related events within 30 days after initial niraparib administration) was justified by the incidences of a global pivotal phase 3 study and its post-hoc safety analysis on thrombocytopenia, the major hematological adverse event of niraparib. The overall safety analysis examined other treatment-emergent adverse events (TEAEs). Results: Enrolled patients (n=19) had a median (min, max) body weight of 53.9 (40.8–79.1) kg; all but one patient weighed <77 kg. Most (94.7%) patients initially received niraparib 300 mg/day but this decreased in subsequent cycles (mean±standard deviation dose intensity, 191.6±65.7 mg/day). In total, 6/19 (31.6%) patients experienced grade 3 or 4 thrombocytopenia-related events within 30 days of initial niraparib administration.Other common TEAEs included nausea, and decreased platelet or neutrophil counts. No progression-free or overall survival events occurred; only 1 of 4 response-evaluable patients had a post-baseline tumor assessment (stable disease). Conclusion The incidence of grade 3 or 4 thrombocytopenia-related events in Japanese ovarian cancer patients was similar to that in the corresponding non-Japanese study. Overall, the safety profile was acceptable and consistent with the known safety profile and previous experience with niraparib.